Dezhan Healthcare (000813) Fundamentals 2026 — Revenue Analysis | SniperIQ
Dezhan Healthcare (000813) is a CN-listed Healthcare company in Drug Manufacturers - Specialty & Generic with a market capitalization of ¥6.9B, trading at ¥3.28 on the SHZ. This SniperIQ fundamentals page covers Dezhan Healthcare's valuation, profitability (net margin -90.3%), revenue (¥397M in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Dezhan Healthcare's market cap?
Dezhan Healthcare (000813) has a market capitalization of approximately ¥6.9B, trading at ¥3.28 on the SHZ. Market cap moves with the live share price.
What is Dezhan Healthcare's P/E ratio?
Dezhan Healthcare's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 1.5x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Dezhan Healthcare?
Dezhan Healthcare runs a net profit margin of -90.3%, a gross margin of 52.2%, and an operating margin of -111.9%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Dezhan Healthcare generate?
Dezhan Healthcare reported revenue of ¥397M for fiscal year 2025, with net income of -¥345M and earnings per share (EPS) of -0.16. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Dezhan Healthcare pay a dividend?
Dezhan Healthcare does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Is Dezhan Healthcare financially healthy?
Dezhan Healthcare carries a debt-to-equity ratio of 0.03x and a current ratio of 16.69x, with a market beta of 0.44. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Dezhan Healthcare a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Dezhan Healthcare (000813) the key facts are: market cap ¥6.9B, revenue ¥397M, 52-week range 2.75-5.26. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Dezhan Healthcare's full fundamentals live
Get Dezhan Healthcare's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.